Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
Context Therapeutics reported Q2 net loss of $14.6M (vs $8.8M YoY) and discontinued CT-95; stock fell 30% after-hours. With $43M cash through Q4 2027 and Phase 1 data delayed to Q2 2027, the 55% YTD decline signals investor skepticism on bispecific antibody programs.
Context Therapeutics Inc.
(NASDAQ:CNTX) shares fell 30.45% in Wednesday's after-hours session after the company reported its second-quarter financial results.
The stock closed Wednesday's regular session up 11.45% at $0.69 before falling 30.45% to $0.48 in after-hours trading.
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell-engaging bispecific antibodies for solid tumors.
Its lead programs include CTIM-76 and CT-202.
NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise capital for growth and…
Codexis stock falls after hours after pricing a discounted public offering. Here's why CDXS shares are moving today.
Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
Nexentis stock surged on AI drug discovery news before falling after announcing a $2.9 million offering.
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
Texxon Holding (NASDAQ:NPT) down 0.43%, underperforming with cyclicals leading, mixed signals on chart, driven by demand in China.
